<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; } </style>

United States // News Releases

News Releases

INVESTOR RESOURCES
Filter Releases
 
News Releases
Date Title and Summary View
May 17, 2017
Company to Host an Investor Conference Call on May 18, 2017 at 7:30 a.m. ET IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the Food and Drug Administra...
May 4, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2017. "We are pleased with our progress during the quarter and our solid start to...
Apr 24, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Dr. Jeffrey Carpenter's submission "Refinement of the IFU for the Nellix® System for Endovascular Aneurysm Sealing Based Upon Outcomes From the EVAS F...
Apr 17, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2017 after the market close on Thursday, May 4, 2017. The Company's management will ...
Apr 4, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into an agreement with Deerfield Management ("Deerfield"), a leading healthcare investment organization, to provide Endologix with up to $170...
Mar 31, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patients were treated in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinica...
Mar 13, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chairman and Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference at 8:35 a.m. ET on Wednesday, March ...
Feb 22, 2017
IRVINE, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2016. John McDermott, Endologix Chief Executive Officer, said, "In 2016, we successfully completed the TriVas...
Feb 14, 2017
IRVINE, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) study, a multi-center post-mark...
Feb 7, 2017
IRVINE, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2016 financial results, which will take place on Wednesday, February 22, 2017 after the close of the market. ...
Feb 6, 2017
John McDermott to Continue as Chief Executive Officer IRVINE, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that its Board of Directors has elected to separate the positions of Chairman of the Board and Chief Executive Officer, ef...
Feb 3, 2017
IRVINE, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Vaseem Mahboob, Chief Financial Officer, is scheduled to present at Leerink Partners 6th Annual Global Healthcare Conference in New York, NY. The Leerink Conference will utiliz...
Jan 25, 2017
IRVINE, Calif., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that it received notice from its Notified Body in the European Union that the CE Mark for the AFX® and AFX2 Endovascular AAA Systems has been reinstated, effective immediately....
Jan 25, 2017
IRVINE, Calif., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive 3-year clinical data from the Ovation European Post Market Registry at the 2017 Leipzig Interventional Course (LINC Symposium) in Leipzig, Germany.  The...
Jan 17, 2017
IRVINE, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that the company has resumed shipments of all sizes of AFX®2 Endovascular AAA Systems.  The large diameter sizes of AFX2 were placed on a temporary hold December 27, 2016, to i...
= add release to Briefcase